美国肠易激综合征治疗市场至 2027 年——国家分析和预测，按类型（腹泻型肠易激综合征 (IBS-D)、便秘型肠易激综合征 (IBS-C)、混合型肠易激综合征 (IBS-M)）；产品（利福昔明、依鲁沙多林、鲁比前列酮、利那洛肽等）；分销渠道（医院药房、药店和零售药房、网上药房）
No. of Pages: 76 | Report Code: TIPRE00009741 | Category: Life Sciences
No. of Pages: 76 | Report Code: TIPRE00009741 | Category: Life Sciences
美国肠易激综合症治疗市场预计将从 2019 年的 5.8661 亿美元增至 2027 年的 12.7621 亿美元。预计该市场将以 10.3% 的复合年增长率增长2020-2027年。
市场的增长是由流行率不断提高等因素推动的肠易激综合症和相关疾病的发生率，以及 FDA 批准和批准数量的增加。药物开发。另一方面，产品数量有限和治疗效率低下可能会限制预测年份的市场增长。
烦躁肠综合症治疗市场是一种主要观察到的慢性胃肠道疾病，是由于排便习惯紊乱和腹痛引起的。该病也称为痉挛性结肠、结肠激惹、粘液性结肠炎和痉挛性结肠炎。肠易激综合症会出现腹痛、便秘、腹泻和痉挛等症状。
各地区的卫生系统正在经历显着的增长。肠易激综合症的发生率。根据国际胃肠道疾病基金会公布的数据，在所有肠易激综合征患者中，约40%的人患有轻度IBS，约35%的人患有中度IBS，估计25%的人患有重度IBS。许多人不认识肠易激综合症的症状。某些因素，如食物过敏、胃肠炎的发展阶段、结肠的不规则运动、结肠中血清素的组成异常以及轻度乳糜泻，是引起肠易激综合症的一些危险因素。预计这些因素将加速全球肠易激综合症的患病率。例如，根据 NCBI 2018 年发表的一项研究，肠易激综合症估计每年影响约 10% 至 16% 的美国人口。肠易激综合症如此惊人的患病率可能会在预测期内推动美国肠易激综合症治疗市场的发展。
为了应对针对该国的肠易激综合症，参与肠易激综合症药物开发的公司正在采取建设性措施来实施提高认识计划，旨在提高民众的认识。例如，2018 年，Allergan PLC 和 Ironwood 合作推出了交互式数字目的地平台，鼓励患者接受教育并采取行动。预计此类举措还将推动美国肠易激综合症治疗市场的需求。
美国肠易激综合症治疗-市场细分
< span>
美国肠易激综合症治疗市场 - 按产品
美国肠易激综合症治疗市场 - 作者：
< strong>分销渠道
公司简介
Strategic insights for US Irritable Bowel Syndrome Treatment involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 586.61 Million |
| Market Size by 2027 | US$ 1,276.21 Million |
| Global CAGR (2020 - 2027) | 10.3% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By 类型
|
| Regions and Countries Covered | 美国
|
| Market leaders and key company profiles |
The regional scope of US Irritable Bowel Syndrome Treatment refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The List of Companies - US Irritable Bowel Syndrome Treatment Market
The US Irritable Bowel Syndrome Treatment Market is valued at US$ 586.61 Million in 2019, it is projected to reach US$ 1,276.21 Million by 2027.
As per our report US Irritable Bowel Syndrome Treatment Market, the market size is valued at US$ 586.61 Million in 2019, projecting it to reach US$ 1,276.21 Million by 2027. This translates to a CAGR of approximately 10.3% during the forecast period.
The US Irritable Bowel Syndrome Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the US Irritable Bowel Syndrome Treatment Market report:
The US Irritable Bowel Syndrome Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The US Irritable Bowel Syndrome Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the US Irritable Bowel Syndrome Treatment Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For US Irritable Bowel Syndrome Treatment Market
